Biology:Proinsulin

From HandWiki
Short description: Precursor protein in humans
insulin
Insulin path.svg
Insulin undergoes extensive posttranslational modification along the production pathway. Production and secretion are largely independent; prepared insulin is stored awaiting secretion. Both C-peptide and mature insulin are biologically active. Cell components and proteins in this image are not to scale.
Identifiers
SymbolINS
NCBI gene3630
HGNC6081
OMIM176730
RefSeqNM_000207
UniProtP01308
Other data
LocusChr. 11 p15.5

Proinsulin is the prohormone precursor to insulin made in the beta cells of the Pancreatic Islets, specialized regions of the pancreas. In humans, proinsulin is encoded by the INS gene.[1][2] The pancreatic islets only secrete between 1% and 3% of proinsulin intact.[3] However, because proinsulin has a longer half life than insulin, it can account for anywhere from 5–30% of the insulin-like structures circulating in the blood.[3] There are higher concentrations of proinsulin after meals and lower levels when a person is fasting.[3] Additionally, while proinsulin and insulin have structural differences, proinsulin does demonstrate some affinity for the insulin receptor. Due to the relative similarities in structure, proinsulin can produce between 5% and 10% of the metabolic activity similarly induced by insulin.[3]

Proinsulin is the final single chain protein structure secreted by cells before cleavage into mature insulin.[4] Proinsulin was discovered by Professor Donald F. Steiner of the University of Chicago in 1967.[5]

Structure

Proinsulin is made up of 86 residues in humans (81 in cows),[6] and formed by three distinct chains.[7] The A chain, B chain, and the area connecting the two named the C peptide.[7] The correct structure of proinsulin is crucial for the correct folding of mature insulin, as the placement of the C peptide sets the molecule up to create correctly positioned disulfide bonds in and between the A and B chains.[7][8] There are three disulfide bonds that are necessary for mature insulin to be the correct structure. Two of these disulfide bonds are between the A and B chains, and one is an intra-A chain bond.[7] The disulfide bonds occur between the seventh residues of the A and B chain, the 20th residue of the A chain and the 19th residue of the B chain, and the 6th and 11th residues of the A chain.[9]

The C peptide is between the A and B chains of proinsulin.[7] The connection between the A chain and C peptide is much more stable than the junction between the C peptide and B chain, with alpha helical features being exhibited near the C peptide-A chain connection.[10] The C peptide-A chain junction occurs between residues 64 and 65 of proinsulin. These are lysine and arginine molecules, respectively.[10] The C peptide-B chain connection is between two arginine residues at positions 31 and 32 of proinsulin.[10]

There is conservation of much of the structure of proinsulin among mammalian species, with much of the residue changes seen from one species to another present in the C peptide.[8][11] That said, the residues of the C peptide that are conserved across species interact with similarly conserved residues on the A and B chains.[8] Thus, it is hypothesized that these conserved residues are important for the functionality of mature insulin.[8]

  • Proinsulin 3.png
  • 3D Model of proinsulin - A chain is in blue, b chain in red, c peptide in orange. The dibasic cleavage for c peptide and a chain is in green KR (lysine and arginine), the one for c peptide and b chain is in cyan RR (arginine).

    3D Model of proinsulin - A chain is in blue, b chain in red, c peptide in orange. The dibasic cleavage for c peptide and a chain is in green KR (lysine and arginine), the one for c peptide and b chain is in cyan RR (arginine).

Synthesis and Post-translational Modification

Proinsulin is synthesized on membrane associated ribosomes found on the rough endoplasmic reticulum, where it is folded and its disulfide bonds are oxidized. It is then transported to the Golgi apparatus where it is packaged into secretory vesicles, and where it is processed by a series of proteases to form mature insulin. Mature insulin has 35 fewer amino acids; 4 are removed altogether, and the remaining 31 form the C-peptide. The C-peptide is abstracted from the center of the proinsulin sequence; the two other ends (the B chain and A chain) remain connected by disulfide bonds.[citation needed]

The post translational modification of proinsulin to mature insulin only occurs in the beta cells of the pancreatic islets.[12] When proinsulin is transported through the Golgi apparatus the C-peptide is cleaved.[9] This cleavage occurs with the aid of two endoproteases.[13] Type I endoproteases, PC1 and PC3, disrupt the C peptide-B chain connection.[13] PC2, a type II endoprotease, cleaves the C peptide-A chain bond.[13] The resulting molecule, now mature insulin, is stored as a hexamer in secretory vesicles and is stabilized with [math]\displaystyle{ Zn^{2+} }[/math] ions until it is secreted.[9]

  • Proinsulin evolution.png

Immunogenicity

When insulin was originally purified from bovine or porcine pancreata, all the proinsulin was not fully removed.[14][15] When some people used these insulins, the proinsulin may have caused the body to react with a rash, to resist the insulin, or even to make dents or lumps in the skin at the place where the insulin was injected. This can be described as an iatrogenic injury due to slight differences between the proinsulin of different species. Since the late 1970s, when highly purified porcine insulin was introduced, and the level of insulin purity reached 99%, this ceased to be a significant clinical issue.[16] With respect to their influence on insulin pharmacokinetics, moderate concentrations of certain insulin antibodies may be of positive advantage to all diabetics without endogenous insulin secretion (e.g. people with type 1 diabetes) because insulin binding antibodies effectively increase the insulin's clearance rate and distribution space and help to prolong its pharmacological and biological half lives.[17][clarification needed]

Medical Relevance

Historically, the focus of many insulin related metabolic diseases has focused on mature insulin. However, in recent years the importance of studying the structure and function of proinsulin or proinsulin:insulin ratio[18] in relation to these diseases has become increasingly clear.

Diabetes Mellitus

Increased levels of proinsulin in the circulatory system relative to mature insulin concentrations can indicate impending insulin resistance and the development of type 2 diabetes.[19] Additional problems with proinsulin that can lead to diabetes include mutations in the number of cysteines present, which could affect correct folding.[9] If the mutation causes only a mild change it could simply stress the endoplasmic reticulum’s ability to properly fold the protein.[9] This stress, after a while, would lead to a decrease in the number of β-cells producing mature insulin, and would then lead to diabetes mellitus.[9]

Neonatal Diabetes Mellitus

Postnatal proinsulin is crucial for metabolic regulation. However, proinsulin in neonates is important for normal development of the nerves of the eye, development of the heart, and general survival of embryonic cells.[20] Regulation of the concentration of proinsulin during embryonic development is crucial, as too much or too little of the peptide can cause defects and death of the fetus.[20] Thus far in the study of neonatal diabetes mellitus, only amino acid change mutations found in the B domain lead to the disease.[9]

See also

References

  1. ↑ "Entrez Gene: INS insulin". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=3630. 
  2. ↑ "Sequence of the human insulin gene". Nature 284 (5751): 26–32. March 1980. doi:10.1038/284026a0. PMID 6243748. Bibcode: 1980Natur.284...26B. 
  3. ↑ 3.0 3.1 3.2 3.3 "Interpretation for 80908 Proinsulin, Plasma". http://www.mayomedicallaboratories.com/interpretive-guide/?alpha=P&unit_code=80908. 
  4. ↑ "Effects of estrogenic hormones on uteroplacental hemodynamics and progesterone production in the sheep". International Journal of Fertility 23 (3): 219–23. 1995. PMID 40897. 
  5. ↑ "Donald F. Steiner MD, 1930-2014: discoverer of proinsulin". Proceedings of the National Academy of Sciences of the United States of America 112 (4): 940–1. January 2015. doi:10.1073/pnas.1423774112. PMID 25561547. Bibcode: 2015PNAS..112..940P. 
  6. ↑ Universal protein resource accession number P01308 for " INS_HUMAN" at UniProt.
  7. ↑ 7.0 7.1 7.2 7.3 7.4 "The structure of bovine proinsulin". The Journal of Biological Chemistry 246 (9): 2780–95. May 1971. doi:10.1016/S0021-9258(18)62252-5. PMID 4928892. http://www.jbc.org/content/246/9/2780. 
  8. ↑ 8.0 8.1 8.2 8.3 "Proinsulin: a proposed three-dimensional structure". The Journal of Biological Chemistry 250 (16): 6291–5. August 1975. doi:10.1016/S0021-9258(19)41065-X. PMID 808541. http://www.jbc.org/content/250/16/6291. 
  9. ↑ 9.0 9.1 9.2 9.3 9.4 9.5 9.6 "Proinsulin and the genetics of diabetes mellitus". The Journal of Biological Chemistry 284 (29): 19159–63. July 2009. doi:10.1074/jbc.R109.009936. PMID 19395706. 
  10. ↑ 10.0 10.1 10.2 "Solution structure of proinsulin: connecting domain flexibility and prohormone processing". The Journal of Biological Chemistry 285 (11): 7847–51. March 2010. doi:10.1074/jbc.c109.084921. PMID 20106974. 
  11. ↑ "Sequence of the human insulin gene". Nature 284 (5751): 26–32. March 1980. doi:10.1038/284026a0. PMID 6243748. Bibcode: 1980Natur.284...26B. 
  12. ↑ "Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin". The Journal of Biological Chemistry 269 (8): 6241–5. February 1994. doi:10.1016/S0021-9258(17)37593-2. PMID 8119968. http://www.jbc.org/content/269/8/6241.full.pdf. 
  13. ↑ 13.0 13.1 13.2 "Sequence requirements for proinsulin processing at the B-chain/C-peptide junction". The Biochemical Journal 310 (3): 869–74. September 1995. doi:10.1042/bj3100869. PMID 7575420. 
  14. ↑ "Immunogenicity of highly purified bovine insulin: a comparison with conventional bovine and highly purified human insulins". Diabetologia 28 (9): 667–70. September 1985. doi:10.1007/BF00291973. PMID 3905477. 
  15. ↑ "Insulin Pharmacology, Type of Regimens and Adjustments". Endotext.com. http://www.endotext.org/diabetes/diabetes17/diabetes17.htm. 
  16. ↑ "The new insulins. Their characteristics and clinical indications". Drugs 24 (5): 401–13. November 1982. doi:10.2165/00003495-198224050-00003. PMID 6756879. https://www.semanticscholar.org/paper/05663202b5ffa42441c735516788e4fa9eeece68. 
  17. ↑ "Influence of insulin antibodies on pharmacokinetics and bioavailability of recombinant human and highly purified beef insulins in insulin dependent diabetics". British Medical Journal 290 (6483): 1687–91. June 1985. doi:10.1136/bmj.290.6483.1687. PMID 3924216. 
  18. ↑ "Increased β-Cell Workload Modulates Proinsulin-to-Insulin Ratio in Humans". Diabetes 67 (11): 2389–2396. November 2018. doi:10.2337/db18-0279. PMID 30131390. 
  19. ↑ "The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects". Diabetes 46 (12): 1990–5. December 1997. doi:10.2337/diab.46.12.1990. PMID 9392485. 
  20. ↑ 20.0 20.1 "Proinsulin in development: New roles for an ancient prohormone". Diabetologia 49 (6): 1142–50. June 2006. doi:10.1007/s00125-006-0232-5. PMID 16596360. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:Proinsulin&oldid=3626212"